FDA accepts Priority Review of Odronextamab BLA for Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma.

This article summarized the latest R&D progress of acetaminophen/butalbital/caffeine, the Mechanism of Action for acetaminophen/butalbital/caffeine, and the drug target R&D trends for acetaminophen/butalbital/caffeine.

TIL therapy uses the patient's own immune cells from the solid tumor microenvironment to kill tumor cells.

This article summarized the latest R&D progress of carglumic acid, the Mechanism of Action for carglumic acid, and the drug target R&D trends for carglumic acid.

IMUNON released preliminary PFS and OS statistics related to IMNN-001 from its Phase 1/2 OVATION 2 Investigation.

This article summarized the latest R&D progress of Regadenoson, the Mechanism of Action for Regadenoson, and the drug target R&D trends for Regadenoson.

Fusion protein technology is a purposeful gene fusion and protein expression method to obtain large amounts of standard fusion proteins.

This article summarized the latest R&D progress of Revefenacin, the Mechanism of Action for Revefenacin, and the drug target R&D trends for Revefenacin.

Structure Therapeutics has revealed encouraging results from its Phase 1b incremental dose study of its exclusive oral GLP-1 receptor agonist, GSBR-1290, in overweight or obese individuals.

This article summarized the latest R&D progress of Risedronate sodium, the Mechanism of Action for Risedronate sodium, and the drug target R&D trends for Risedronate sodium.

Recently, AstraZeneca published in JMC, detailing the development of the inhaled JAK1 inhibitor AZD4604.

This article summarized the latest R&D progress of Roxadustat, the Mechanism of Action for Roxadustat, and the drug target R&D trends for Roxadustat.